Literature DB >> 15937510

Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.

M Steiner1, S Matthes-Martin, A Attarbaschi, M Minkov, N Grois, E Unger, W Holter, J Vormoor, A Wawer, M Ouachee, W Woessmann, H Gadner.   

Abstract

Children with multisystem Langerhans cell histiocytosis (LCH) and risk organ involvement who fail to respond to conventional chemotherapy have an extremely poor prognosis. Myeloablative stem cell transplantation (SCT) as a possible salvage approach for these patients has been associated with a high risk of transplant-related mortality. Therefore, allogeneic stem cell transplantation following a reduced-intensity conditioning regimen (RIC-SCT) has recently been performed as an alternative salvage approach. We report on the experience with allogeneic RIC-SCT in nine pediatric high-risk LCH patients. Conditioning regimen included fludarabine in all patients, melphalan in eight patients, total lymphoid irradiation in six patients, total body irradiation in two, antithymocyte globulin in five, and Campath in four patients. RIC-SCT was well tolerated with regard to common procedure-related complications. Two patients died 50 and 69 days after RIC-SCT, respectively. Seven out of the nine patients survived and showed no signs of disease activity (including one with nonengraftment and full autologous hematopoietic recovery) after median follow-up of 390 days post-SCT. Based on this observation, we conclude that RIC-SCT is a feasible procedure with low transplant-related morbidity and mortality and a promising new salvage approach for high-risk LCH patients with resistant risk organ involvement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937510     DOI: 10.1038/sj.bmt.1705015

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  Treatment of relapsed/refractory langerhans cell histiocytosis: a single centre experience.

Authors:  Vikas Dua; Satya Prakash Yadav; Anupam Sachdeva
Journal:  Indian J Pediatr       Date:  2013-06-06       Impact factor: 1.967

2.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

3.  Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning.

Authors:  Paul A Veys; Vasanta Nanduri; K Scott Baker; Wensheng He; Giuseppe Bandini; Andrea Biondi; Arnaud Dalissier; Jeffrey H Davis; Gretchen M Eames; R Maarten Egeler; Alexandra H Filipovich; Alain Fischer; Herbert Jürgens; Robert Krance; Edoardo Lanino; Wing H Leung; Susanne Matthes; Gérard Michel; Paul J Orchard; Anna Pieczonka; Olle Ringdén; Paul G Schlegel; Anne Sirvent; Kim Vettenranta; Mary Eapen
Journal:  Br J Haematol       Date:  2015-03-27       Impact factor: 6.998

4.  Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH.

Authors:  Alexandra Kolenová; Raphaela Schwentner; Gunhild Jug; Ingrid Simonitsch-Klupp; Christoph Kornauth; Lukáš Plank; Júlia Horáková; Ivana Bodová; Tomáš Sýkora; Lucia Geczová; Wolfgang Holter; Milen Minkov; Caroline Hutter
Journal:  Blood Adv       Date:  2017-02-02

Review 5.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 6.  Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.

Authors:  Marie-Luise Berres; Carl E Allen; Miriam Merad
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

7.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

8.  Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy.

Authors:  Mariko Minami; Takahiro Shima; Koji Kato; Hidetaka Yamamoto; Kenji Tsuchihashi; Seido Oku; Tomonori Shimokawa; Taro Tochigi; Goichi Yoshimoto; Kenjiro Kamezaki; Katsuto Takenaka; Hiromi Iwasaki; Yoshinao Oda; Toshihiro Miyamoto; Koichi Akashi
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

Review 9.  Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis.

Authors:  Kazuko Kudo; Miho Maeda; Nobuhiro Suzuki; Hirokazu Kanegane; Shouichi Ohga; Eiichi Ishii; Yoko Shioda; Toshihiko Imamura; Shinsaku Imashuku; Yukiko Tsunematsu; Mikiya Endo; Akira Shimada; Yuuki Koga; Yoshiko Hashii; Maiko Noguchi; Masami Inoue; Ken Tabuchi; Akira Morimoto
Journal:  Int J Hematol       Date:  2019-11-22       Impact factor: 2.490

Review 10.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.